Lunit Valuation
Is A328130 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A328130 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: A328130 (₩55000) is trading below our estimate of fair value (₩90405.49)
Significantly Below Fair Value: A328130 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A328130?
Key metric: As A328130 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is A328130's PS Ratio? | |
|---|---|
| PS Ratio | 40.3x |
| Sales | ₩39.54b |
| Market Cap | ₩1.59t |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 40x |
| Enterprise Value/EBITDA | -26.1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does A328130's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 11.5x | ||
A315640 DEEPNOID | 15.2x | 46.2% | ₩141.0b |
A032620 UBcare | 1x | n/a | ₩178.6b |
A311690 CJ Bioscience | 28.5x | n/a | ₩139.6b |
A071200 INFINITT Healthcare | 1.1x | n/a | ₩109.2b |
A328130 Lunit | 40.3x | 49.9% | ₩1.6t |
Price-To-Sales vs Peers: A328130 is expensive based on its Price-To-Sales Ratio (40.3x) compared to the peer average (11.5x).
Price to Sales Ratio vs Industry
How does A328130's PS Ratio compare vs other companies in the Asian Healthcare Services Industry?
| 4 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 4 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: A328130 is expensive based on its Price-To-Sales Ratio (40.3x) compared to the Asian Healthcare Services industry average (4.9x).
Price to Sales Ratio vs Fair Ratio
What is A328130's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 40.3x |
| Fair PS Ratio | 59x |
Price-To-Sales vs Fair Ratio: A328130 is good value based on its Price-To-Sales Ratio (40.3x) compared to the estimated Fair Price-To-Sales Ratio (59x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Access Bio
₩188.3b
Engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide.
A950130
₩5,570.00
7D
2.0%
1Y
-37.1%
Vieworks
₩192.8b
Develops, manufactures, and sells imaging systems and solutions.
A100120
₩21,000.00
7D
3.4%
1Y
-24.2%
Wonbiogen
₩43.5b
Develops and sells medical equipment in South Korea.
A307280
₩1,225.00
7D
-1.1%
1Y
-21.6%